O
MREO

OrbiMed’s Mereo BioPharma MREO Stock Holding History

OrbiMed’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,747,891
Closed -$5.48M – 129
2023
Q1 		$5.48M Sell
7,747,891
-2,857,631
-27% -$2.57M 0.11% 102
2022
Q4 		$7.95M Hold
10,605,522
– – 0.15% 80
2022
Q3 		$9.13K Buy
10,605,522
+8,004,054
+308% +$9.79M 0.17% 88
2022
Q2 		$10.9K Sell
2,601,468
-7,553,342
-74% -$5.85M 0.2% 88
2022
Q1 		$19.3M Buy
+10,154,810
New +$13.1M 0.31% 67
2021
Q4 		– Sell
-17,264,764
Closed -$34.5M – 68
2021
Q3 		$41.8M Buy
+17,264,764
New +$45.7M 0.46% 60
2021
Q2 		– Hold
0
– – – 54
2021
Q1 		– Hold
0
– – – 52
2020
Q4 		– Hold
0
– – – 63

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OrbiMed's MREO Position: Q2 2023 in Review

OrbiMed sold out of Mereo BioPharma (MREO) in Q2 2023, closing a stake of 7,747,891 shares — an estimated $5.48M sold.

OrbiMed first reported a position in MREO in Q3 2021 and held it in 6 quarters. The position peaked at $41.8M in Q3 2021. 53 funds tracked by Wall St. Rank hold MREO as of Q2 2023.

  • OrbiMed reported no remaining Mereo BioPharma position as of Q2 2023 after selling out during the quarter.
  • OrbiMed sold 7,747,891 Mereo BioPharma shares in Q2 2023, an estimated $5.48M.
  • OrbiMed first reported a position in Mereo BioPharma in Q3 2021 and held it in 6 quarters.
  • OrbiMed's Mereo BioPharma position peaked at $41.8M in Q3 2021.
  • 53 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2023.

Based on OrbiMed's 13F filing for Q2 2023, filed 14 Aug 2023.